当前位置: 首页 >> 检索结果
共有 1652 条符合本次的查询结果, 用时 1.9142555 秒

961. The chips are down for Helicobacter pylori.

作者: J C Atherton.
来源: Gut. 2002年50卷3期293-4页

962. Molecular testing for antibiotic resistance in Helicobacter pylori.

作者: R J Owen.
来源: Gut. 2002年50卷3期285-9页
An estimated 7.5 million individuals in England and Wales are actively infected with Helicobacter pylori and hence knowledge of local resistance rates is of growing importance. Also, information on strain resistance following treatment failure is crucial in selecting an appropriate regimen as the development of bacterial resistance to antibiotics makes retreatment difficult. Molecular test methods may have an impact on improving the availability and accuracy of information on H pylori antimicrobial resistance to guide in the selection of primary as well as secondary backup treatment regimens.

963. Guidelines on the management of osteoporosis associated with chronic liver disease.

作者: Jane D Collier.;M Ninkovic.;J E Compston.
来源: Gut. 2002年50 Suppl 1卷Suppl 1期i1-9页

964. The non-H pylori helicobacters: their expanding role in gastrointestinal and systemic diseases.

作者: J G Fox.
来源: Gut. 2002年50卷2期273-83页
The number of species in the genus Helicobacter has rapidly expanded over the past decade. The genus now includes at least 24 formally named species as well as numerous other helicobacters awaiting formal naming. This review highlights the expanding role that other helicobacters, although not as well known as H pylori, play in gastrointestinal and systemic disease in humans.

965. Understanding selective trafficking of lymphocyte subsets.

作者: M Heydtmann.;D H Adams.
来源: Gut. 2002年50卷2期150-2页

966. Gene therapy for liver diseases: recent strategies for treatment of viral hepatitis and liver malignancies.

作者: V Schmitz.;C Qian.;J Ruiz.;B Sangro.;I Melero.;G Mazzolini.;I Narvaiza.;J Prieto.
来源: Gut. 2002年50卷1期130-5页
Gene therapy has emerged as a powerful and very plastic tool to regulate biological functions in diseased tissues with application in virtually all medical fields. An increasing number of experimental and clinical studies underline the importance of genes as curative agents in the future. However, intense research is needed to evaluate the potential of gene therapy to improve efficacy and minimise the toxicity of the procedure.

967. Treatment of colorectal metastases: surgery, cryotherapy, or radiofrequency ablation.

作者: J N Primrose.
来源: Gut. 2002年50卷1期1-5页
The liver is the most common site of metastases from colorectal cancer. There has therefore been growing interest in how liver metastases may be ablated. The most common techniques for ablation of liver metastases are surgical resection, cryotherapy, and increasingly in recent years, radiofrequency ablation.

968. Portal hypertensive gastropathy and gastric antral vascular ectasia (GAVE) syndrome.

作者: K W Burak.;S S Lee.;P L Beck.
来源: Gut. 2001年49卷6期866-72页

969. Sodium in preascitic cirrhosis: please pass the salt.

作者: J Clària.;J Rodés.
来源: Gut. 2001年49卷6期748-9页

970. Monocytes or T cells in Crohn's disease: does IL-16 allow both to play at that game?

作者: S Schreiber.
来源: Gut. 2001年49卷6期747-8页

971. The continuing tale of cytokeratins in Barrett's mucosa: as you like it.

作者: A Latchford.;B Eksteen.;J Jankowski.
来源: Gut. 2001年49卷6期746-7页

972. The hepatorenal syndrome.

作者: L Dagher.;K Moore.
来源: Gut. 2001年49卷5期729-37页

973. Improving prognosis following a first variceal haemorrhage over four decades.

作者: P A McCormick.;C O'Keefe.
来源: Gut. 2001年49卷5期682-5页
Variceal bleeding is a frequent cause of death in patients with cirrhosis and portal hypertension. Over the past 40 years a number of new techniques have been introduced to control active variceal haemorrhage. Many randomised controlled trials were performed to evaluate these new therapies. While most have demonstrated efficacy in controlling haemorrhage few showed improved survival.

974. Antagonist: Should we eradicate Helicobacter pylori before long term antireflux therapy?

作者: J W Freston.
来源: Gut. 2001年49卷5期616-7页

975. Protagonist: Should we eradicate Helicobacter pylori before long term antireflux therapy?

作者: J Labenz.
来源: Gut. 2001年49卷5期614-6页

976. Genomics at work: the global gene response to enteric bacteria.

作者: D Kelly.;S Conway.
来源: Gut. 2001年49卷5期612-3页

977. Intravenous omeprazole after endoscopic treatment of bleeding peptic ulcers.

作者: K R Palmer.
来源: Gut. 2001年49卷5期610-1页

978. Non-pylori Helicobacter species in humans.

作者: J L O'Rourke.;M Grehan.;A Lee.
来源: Gut. 2001年49卷5期601-6页

979. Autoimmune hepatitis and its variant syndromes.

作者: Z Ben-Ari.;A J Czaja.
来源: Gut. 2001年49卷4期589-94页

980. Regression of gastric high grade mucosa associated lymphoid tissue (MALT) lymphoma after Helicobacter pylori eradication.

作者: C Montalban.;A Santon.;D Boixeda.;C Bellas.
来源: Gut. 2001年49卷4期584-7页
Most low grade gastric lymphomas arising from the mucosa associated lymphoid tissue (MALT) are related to Helicobacter pylori colonisation. Cases with disease limited to the stomach can be cured after H pylori eradication and remain in remission for years. In contrast, high grade lymphomas of the stomach, although also related to H pylori, do not usually respond to eradication treatment.
共有 1652 条符合本次的查询结果, 用时 1.9142555 秒